Eli Lilly and Company News - September 15, 2026

Eli Lilly taps QurCan for brain-penetrating drugs, targeting nervous system diseases

Eli Lilly and Company partnered with Canadian biotech QurCan Therapeutics to develop genetic medicines for the central and peripheral nervous systems. The...

Eli Lilly unveils retatrutide data, reporting 20.8% weight loss in diabetes trial

Eli Lilly and Company will present new cardiometabolic data at the European Association for the Study of Diabetes (EASD) 2026 meeting. The presentations...